Data gathered: November 27
Alternative Data for Coherus BioSciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 19,000 | Sign up | Sign up | Sign up |
| Google Trends | 13 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 54 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,531 | Sign up | Sign up | Sign up |
| Twitter Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
About Coherus BioSciences
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilars and immuno-oncology market primarily in the United States. The company is headquartered in Redwood City, California.
| Price | $1.26 |
| Target Price | Sign up |
| Volume | 2,940,000 |
| Market Cap | $139M |
| Year Range | $0.67 - $2.51 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Q3 2024 Coherus BioSciences Inc Earnings CallNovember 7 - Yahoo |
Coherus BioSciences Inc (CHRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...November 6 - Yahoo |
|
 |
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call TranscriptNovember 6 - SeekingAlpha |
 |
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue EstimatesNovember 6 - Yahoo |
|
Coherus BioSciences: Q3 Earnings SnapshotNovember 6 - Yahoo |
 |
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 6 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 71M | 57M | 14M | -11M | -4.8M | -0.010 |
| Q2 '24 | 52M | 64M | -12M | -13M | -19M | -0.140 |
| Q1 '24 | 66M | 93M | -27M | 103M | -41M | -0.320 |
| Q4 '23 | 81M | 135M | -54M | -80M | -68M | -0.620 |
| Q3 '23 | 64M | 81M | -17M | -40M | -29M | -0.410 |
Insider Transactions View All
| Lanfear Dennis M filed to sell 731,693 shares at $2. November 24 '23 |
Similar companies
Read more about Coherus BioSciences (CHRS) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, sentiment, webpage traffic, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions & customer reviews.
What is the Market Cap of Coherus BioSciences?
The Market Cap of Coherus BioSciences is $139M.
What is the current stock price of Coherus BioSciences?
Currently, the price of one share of Coherus BioSciences stock is $1.26.
How can I analyze the CHRS stock price chart for investment decisions?
The CHRS stock price chart above provides a comprehensive visual representation of Coherus BioSciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Coherus BioSciences shares. Our platform offers an up-to-date CHRS stock price chart, along with technical data analysis and alternative data insights.
Does CHRS offer dividends to its shareholders?
As of our latest update, Coherus BioSciences (CHRS) does not offer dividends to its shareholders. Investors interested in Coherus BioSciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Coherus BioSciences?
Some of the similar stocks of Coherus BioSciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.